Testing of a New Therapeutic Vibration Device to Reduce Neuromuscular Weakness in Hospitalized Patients (Hospital Testing)
Primary Purpose
Critically Ill
Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Therapeutic Vibration Device
Sponsored by
About this trial
This is an interventional basic science trial for Critically Ill
Eligibility Criteria
Inclusion Criteria:
- sick patients admitted to the ICUs at University of Michigan hospital
Exclusion Criteria:
- Acute Spinal Cord Injury
- Acute vertebral body fracture or injury
- Acute stroke or intracerebral hemorrhage
- Hemodynamic instability or other event/condition believed by care team to warrant nonparticipation
- Known pregnancy
- Prisoner
Sites / Locations
- University of Michigan
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Hospitalized patients
Arm Description
This phase will recruit hospitalized bedridden patients who will be vibrated with the prototype device using various vibration frequencies to determine which frequency produces the optimal physiologic response. Physiologic responses will be determined with a number of devices capable of measuring such things as tissue oxygenation, oxygen consumption, and muscle activity. Blood samples will also be taken to measure certain chemical markers associated with activity and increase blood flow. They may receive multiple 5 minute episodes of various vibration frequencies.
Outcomes
Primary Outcome Measures
StO2
Tissue hemoglobin oxygen saturation (StO2) using near infrared spectroscopy of the thighs, biceps, and brain.
VO2
Oxygen consumption using a VO2 monitor and mask
EMG
Muscle contraction using noninvasive electromyography
Blood markers - serum glucose
Serum glucose (mg/dl)
Blood markers - lipids
lipids (mg/dl)
Blood markers - cytokines
inflammatory cytokines IL-6, TNFα, IL-1β (pg/ml)
Blood markers - growth hormone
growth hormone (ng/ml)
Blood markers - cortisol
cortisol (μg/dL)
bone turnover markers
C-terminal telopeptide of type I collagen (CTX-I) and tartrate-resistant acid phosphatase 5b (U/L)
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05352100
Brief Title
Testing of a New Therapeutic Vibration Device to Reduce Neuromuscular Weakness in Hospitalized Patients (Hospital Testing)
Official Title
Testing of a New Therapeutic Vibration Device to Reduce Neuromuscular Weakness in Hospitalized Patients (Hospital Testing)
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Withdrawn
Why Stopped
Researchers decided to move to another technological platform which will require a new record when that research is ready to launch.
Study Start Date
November 2022 (Anticipated)
Primary Completion Date
March 2025 (Anticipated)
Study Completion Date
March 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Michigan
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Objective: Test the ability of vibration to produce physiologic, biochemical, and anatomic changes consistent with exercise that would help prevent the development of muscle weakness that occurs when patients are immobile for long periods of time.
Detailed Description
During critical illness, patients who are immobilized for more than a few days develop severe muscle and nerve weakness despite receiving full supportive care, which may include physical therapy. In patients requiring mechanical ventilation (a device that breaths for them) for longer than 7 days, the incidence of ICU-acquired weakness is reported to be between 25% and 60%. Such weakness may contribute to increased duration of mechanical ventilation, increased length of stay in the ICU and hospital, and poor quality of life among survivors. This is part of the newly recognized Post Intensive Care Syndrome (PICS). Moreover, patients who are transferred from the ICU to a high-dependency unit (HDU), intensive therapy unit (ITU), post-operative therapy or outpatient ambulatory care need to be mobile as well as awake for any physical therapy. Patients affected by sepsis (severe blood stream infections), osteoarthritis, spinal cord injury, stroke, multiple sclerosis, cerebral palsy, cancer, and other illnesses suffer muscle loss and weakness. Early mobilization (EM) has demonstrated the ability to significantly reduce the detrimental effects of prolonged immobilization such as polyneuropathy and myopathy (nerve damage and muscle weakness), which in turn reduces the time patients spend on mechanical ventilation and the overall length of hospital stay. EM treatments include intense physical therapy, cycle ergometry, transcutaneous electrical muscle stimulation (TEMS) and continuous lateral rotational therapy (CLRT). However, carrying out intense physical therapy using therapists is impractical (especially at smaller hospitals) and cannot be implemented in heavily sedated patients (patients who cannot cooperate). Evidence suggests that vibration may be capable of producing adequate muscle contraction via muscle-spinal loops that may be sufficient to reduce or prevent nerve damage and muscle weakness caused by prolonged immobilization thus serving as an effective treatment making patients stronger when they leave the ICU.
The purpose of this study is to test a prototype vibration device and strategy on its ability to exercise large muscle groups, increase muscle blood flow, and increase circulating levels of blood chemicals associated with exercise/activity. The study will be used to find optimal vibration frequencies that provide maximal evidence of associated muscle activity. Eventually the investigators hope to see a vibration device capable of delivering a more effective therapy compared to the smaller gains derived from traditional measures of physical therapy in critically ill patients such as TEMS, CLRT and cycle ergometry to patients. The vibration device may directly benefit the patient in terms of health, length of stay and reduced re-admission, hospital staff in terms of productivity (i.e., through reduction in nursing effort) and the hospital in terms of reduced cost and return on investment. Its value is also envisioned in many other populations of immobilized acutely ill and injured patients as well as those with chronic conditions.
Originally registered as a single record, (NCT03479008) this registration represents the intervention and outcomes of testing with hospitalized patients. NCT03479008 will remain open until it is certain that no additional modifications of the device are required to go through a new round of iterative testing with healthy volunteers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critically Ill
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Hospitalized patients
Arm Type
Experimental
Arm Description
This phase will recruit hospitalized bedridden patients who will be vibrated with the prototype device using various vibration frequencies to determine which frequency produces the optimal physiologic response. Physiologic responses will be determined with a number of devices capable of measuring such things as tissue oxygenation, oxygen consumption, and muscle activity. Blood samples will also be taken to measure certain chemical markers associated with activity and increase blood flow. They may receive multiple 5 minute episodes of various vibration frequencies.
Intervention Type
Diagnostic Test
Intervention Name(s)
Therapeutic Vibration Device
Intervention Description
The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
Primary Outcome Measure Information:
Title
StO2
Description
Tissue hemoglobin oxygen saturation (StO2) using near infrared spectroscopy of the thighs, biceps, and brain.
Time Frame
2 hours
Title
VO2
Description
Oxygen consumption using a VO2 monitor and mask
Time Frame
2 hours
Title
EMG
Description
Muscle contraction using noninvasive electromyography
Time Frame
2 hours
Title
Blood markers - serum glucose
Description
Serum glucose (mg/dl)
Time Frame
On the day of device use (1 day)
Title
Blood markers - lipids
Description
lipids (mg/dl)
Time Frame
On the day of device use (1 day)
Title
Blood markers - cytokines
Description
inflammatory cytokines IL-6, TNFα, IL-1β (pg/ml)
Time Frame
On the day of device use (1 day)
Title
Blood markers - growth hormone
Description
growth hormone (ng/ml)
Time Frame
On the day of device use (1 day)
Title
Blood markers - cortisol
Description
cortisol (μg/dL)
Time Frame
On the day of device use (1 day)
Title
bone turnover markers
Description
C-terminal telopeptide of type I collagen (CTX-I) and tartrate-resistant acid phosphatase 5b (U/L)
Time Frame
On the day of device use (1 day)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
sick patients admitted to the ICUs at University of Michigan hospital
Exclusion Criteria:
Acute Spinal Cord Injury
Acute vertebral body fracture or injury
Acute stroke or intracerebral hemorrhage
Hemodynamic instability or other event/condition believed by care team to warrant nonparticipation
Known pregnancy
Prisoner
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Benjamin S Bassin, MD
Organizational Affiliation
University of Michigan
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Testing of a New Therapeutic Vibration Device to Reduce Neuromuscular Weakness in Hospitalized Patients (Hospital Testing)
We'll reach out to this number within 24 hrs